Adjuvant immunotherapy (BCG) in stage D prostate cancer

P. D. Guinan; T. John; G. Baumgartner; B. Sundar; R. J. Ablin

doi:10.1097/00000421-198202000-00012

Adjuvant immunotherapy (BCG) in stage D prostate cancer

P. D. Guinan, T. John, G. Baumgartner, B. Sundar, R. J. Ablin

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p<0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).

Original language	English (US)
Pages (from-to)	65-68
Number of pages	4
Journal	Unknown Journal
Volume	5
Issue number	1
DOIs	https://doi.org/10.1097/00000421-198202000-00012
State	Published - 1982
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-198202000-00012

Cite this

@article{498c41c252e84e24b9ea3372a8ea20d1,

title = "Adjuvant immunotherapy (BCG) in stage D prostate cancer",

abstract = "Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p<0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).",

author = "Guinan, {P. D.} and T. John and G. Baumgartner and B. Sundar and Ablin, {R. J.}",

year = "1982",

doi = "10.1097/00000421-198202000-00012",

language = "English (US)",

volume = "5",

pages = "65--68",

journal = "Nuclear Physics A",

issn = "0375-9474",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Adjuvant immunotherapy (BCG) in stage D prostate cancer

AU - Guinan, P. D.

AU - John, T.

AU - Baumgartner, G.

AU - Sundar, B.

AU - Ablin, R. J.

PY - 1982

Y1 - 1982

N2 - Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p<0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).

AB - Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p<0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).

UR - http://www.scopus.com/inward/record.url?scp=0020328421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020328421&partnerID=8YFLogxK

U2 - 10.1097/00000421-198202000-00012

DO - 10.1097/00000421-198202000-00012

M3 - Article

AN - SCOPUS:0020328421

VL - 5

SP - 65

EP - 68

JO - Nuclear Physics A

JF - Nuclear Physics A

SN - 0375-9474

IS - 1

ER -

Adjuvant immunotherapy (BCG) in stage D prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this